CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 200 target
Drug / intervention
KN035biological
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Histologically confirmed locally advanced or metastatic colorectal carcinoma or other malignant solid tumors
  • ✓MMR deficient or MSI-H status confirmed
  • ✓At least one measurable lesion
  • ✓ECOG performance status 0 or 1
Key exclusion· 12
  • ✕Investigational agent or device within 4 weeks, or anti-tumor treatment within 2 weeks
  • ✕Not recovered to CTCAE Grade 1 or better from prior therapy side effects
  • ✕Prior immune checkpoint agonist/inhibitor therapy
  • ✕Major surgery within 4 weeks of dosing

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03667170
NCT03667170Phase 2RecruitingOn TrackUpdated 3mo ago
Long Recruiting
CompareCT.gov

Study of KN035 as Monotherapy in Patients With Advanced Mismatched Repair Deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors

3D Medicines (Sichuan) Co., Ltd.·interventional·Posted Sep 12, 2018·Updated Mar 25, 2026

In Brief

A Phase 2 clinical trial evaluating KN035 for Solid Tumor. Currently recruiting, targeting 200 participants across 1 site.

Detailed Summary

In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with KN035 monotherapy. For colorectal cancer participants, who are required to have been previously treated with standard therapies , other solid tumor participants, who are required to have been previously treated with at least one line of systemic standard of care therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
201920202021202220232024202520262027
First PostedSep 12, 2018
Enrollment StartAug 22, 2018
Primary CompletionDec 30, 2026
TodayJul 2, 2026
Enrollment to primary: 8.4 yearsPosted 7.8 years agoPrimary completion in 6 months

Interventions

KN035biological

subcutaneous injection